Drug intelligence / Profile preview

clebopride

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Clebopride is a small molecule dopamine antagonist with antiemetic and prokinetic properties, primarily used to treat functional gastrointestinal disorders such as gastroparesis, functional dyspepsia, gastroesophageal reflux disease (GERD), chronic gastritis, non-ulcer dyspepsia, and to prevent or treat nausea and vomiting—including that associated with chemotherapy[1][2][6][10]. Chemically related to metoclopramide, it acts by selectively blocking dopamine D2 receptors in the gastrointestinal tract and central nervous system. This antagonism enhances acetylcholine release via serotonin 5-HT4 receptor agonism in the GI tract, promoting smooth muscle contraction and improving gastric emptying and intestinal transit[8]. Its primary mechanism is focused on restoring normal gut motility. It is not typically used for other medical conditions outside of GI motility disorders.

Brand names
CleboprideCleboprida
Other names
clebopride malate4-Amino-N-(3-(diethylamino)propyl)-2-methoxybenzamide (chemical name)
02

Targets

DRD2 (Dopamine D2 Receptor)HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on clebopride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clebopride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call